Blood classification and blood response criteria in mycosis fungoides and Sézary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force
Julia Scarisbrick(University Hospital of Zurich), Maarten H. Vermeer(Leiden University Medical Center), Pablo L. Ortiz‐Romero(Hospital Universitario 12 De Octubre), René Stranzenbach(European Organisation for Research and Treatment of Cancer), Emmilia Hodak(Rabin Medical Center), Pietro Quaglino(Department of Medical Sciences), Evangelia Papadavid(National and Kapodistrian University of Athens), M. Bagot(Inserm), Rudolf Stadler(University Hospitals of the Ruhr-University of Bochum), Felicity Evison(NIHR Surgical Reconstruction and Microbiology Research Centre), Robert Knobler(Medical University of Vienna)
Cited by 152
Related Papers
Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
|Journal of Clinical Oncology|2011|657
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
|The Lancet|2017|580
Defining early mycosis fungoides
|Journal of the American Academy of Dermatology|2005|543
Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression
|JAMA Dermatology|2015|452